Results from the Phase III CALGB/SWOG 80405 Trial

June 1, 2014
Richard Goldberg, MD

Richard Goldberg, MD, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting.

Richard Goldberg, MD, Physician-in-Chief at Ohio State’s Comprehensive Cancer Center — James Cancer Hospital and Solove Research Institute, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting. The CALGB/SWOG 80405 trial looked at irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum (mCRC).

<<<

Back to the ASCO 2014 conference page